The minefield… [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2024-02-16 16:59 (63 d 17:58 ago) – Posting: # 23867
Views: 678

Hi Laura,

❝ I know this topic was already discussed here but I am not clarified.

You are not alone…

❝ What do you think is the best statistical analysis to analyse Tmax? Hodges-Lehmann Estimate for example?

Some stuff to chew (not to say to digest):The last one is pretty technical, I must confess, and it was written before the EMA’s product-specific guidances were finalized.
Personally I’m happy with nonparametric methods. They were recommended for ages till 2010 in Europe and still are in some other jurisdictions. I used them in hundreds of my studies. IMHO, it would only make sense if you define a priori a clinically not relevant range and assess the ≈90% CI for inclusion. This range should be defined case by case and not based on this crappy 20% of the median as the EMA stated. As shown in the presentations of Jiří and myself it would require an extremely tight sampling schedule. Furthermore: You might have different ranges dependent on the indication. Think about paracetamol: The range might be narrow as an analgesic, but is completely irrelevant if administered in multiple doses as an antipyretic in children.
There will be an entire session dealing with early exposure at the 6th GBHI workshop (Rockville, 16–17 April 2024).

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
 Admin contact
22,988 posts in 4,825 threads, 1,658 registered users;
102 visitors (0 registered, 102 guests [including 5 identified bots]).
Forum time: 11:58 CEST (Europe/Vienna)

The whole purpose of education is
to turn mirrors into windows.    Sydney J. Harris

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz